Skip to main content
. 2020 Jan 31;9(2):330. doi: 10.3390/cells9020330

Figure 1.

Figure 1

Clinical score after myelin oligodendrocyte glycoprotein 35–55 (MOG35–55) immunization separated by sex and genotype. (A) Clinical course of EAE of IL6:GFAP KO and wild type (WT) mice (left); IL6:SYN1 KO and WT mice (middle); IL6:CX3CR1 KO and WT mice (right). All MOG35-55-immunized mice displayed the prototypical ascending paralysis course starting at 10 dpi, but only IL6:GFAP KO females showed an ameliorated experimental autoimmune encephalomyelitis (EAE) symptomatology. (B) For each animal, we determined the time to disease onset, time to peak disease, peak score, and cumulative score (sum of all scores from disease onset to last day annotated). Only IL6:GFAP KO females showed a decrease in peak score and cumulative score. Number of mice per group as indicated. Results are MEAN ± SEM; ★ p ≤ 0.05 versus WT mice.